GlassScriptPhysician profile
Melvin M Gehrig
NPI 1932181427
$7,011.89
in general payments reported to CMS, 2019-2025
24 companies · $530 in 2025
The $530 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,482 · 2020: $236 · 2021: $676 · 2022: $1,525 · 2023: $1,170 · 2024: $1,393 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,092.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,751.99 | 2019-2025 | Dailies Total1, Precision 1, Total30 |
| Glaukos Corporation | $636.44 | 2021-2024 | Ce-Marked Kxla System, Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Coopervision INC. | $590.33 | 2019-2025 | Biofinity Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Sun Pharmaceutical Industries INC. | $435.31 | 2022-2024 | Cequa |
| Johnson & Johnson Vision Care, INC. | $343.31 | 2022-2023 | Acuvue |
| Bausch & Lomb Americas INC. | $275.30 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Dompe US, INC. | $243.40 | 2023-2024 | Oxervate |
| Optos, INC. | $242.32 | 2021-2022 | |
| Abbvie INC. | $231.17 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $230.16 | 2024-2025 | Xdemvy |
| Allergan, INC. | $214.81 | 2019-2022 | |
| Carl Zeiss Meditec USA, INC. | $132.35 | 2023 | Clarus |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $118.51 | 2019 | |
| Oyster Point Pharma, INC. | $106.52 | 2022-2024 | Tyrvaya, Ryzumvi |
| Regeneron Healthcare Solutions, INC. | $82.32 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $62.23 | 2024 | Flarex, Iheezo, Tobradex St |
| Aerie Pharmaceuticals, INC. | $57.52 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $54.30 | 2022 | |
| Horizon Therapeutics Plc | $48.35 | 2021-2022 | |
| Synergeyes, INC. | $39.33 | 2022 | |
| Genentech USA, INC. | $34.35 | 2022 | |
| Abb Con-Cise Optical Group LLC | $31.56 | 2019 | |
| Ocular Therapeutix, INC. | $28.84 | 2023 | Dextenza |
| Alimera Sciences, INC. | $21.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melvin Gehrig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.